Many advances in the therapy of children with neuroblastoma have been made in the past decade by the Children’s Oncology Group (COG). New trials build upon those successes in an attempt to reduce therapy for lower risk (LR) and intensify therapy for high risk (HR) disease patients.
Current therapies and the nursing care management of LR, HR and relapsed disease will be discussed.
- It's All GREEK To Me! The NEPENTHE Trial for Relapsed/Refractory Neuroblastoma; Personalized Molecularly Targeted Treatment (200)
- A Sustainable Community Engagement Program Model to Address Hematopoietic Cell Transplantation Education Needs for Patients with Sickle Cell Disease (201)
- Nursing Management for the Successful Application of the Chimeric Antigen Receptor (CAR) T-Cell Immunotherapy (212)
- Beyond Pain Crises: Acute Complications of Sickle Cell Disease (202)
- The First 6 months: Health Care in the United States under a new President (213)